GlaxoSmithKline Sales in China Tumble Amid Bribery Probe

LONDON (AP) -- GlaxoSmithKline says its sales of drugs and vaccines in China tumbled in the third quarter as it was hit by bribery investigations there.

Worldwide sales, it says, were flat as growth in the U.S. and Europe helped offset China's 61% drop. Total revenue rose 1% to 6.51 billion pounds ($10.5 billion).

The company was hit by allegations by the Chinese government that four of its employees paid bribes to doctors and hospitals to encourage them to prescribe medications.

Chief Executive Andrew Witty said Wednesday that the decline in China was disappointing but it was too early to judge the long-term impact of the probe.

The company said it expected earnings per share to grow between 3% and 4% this year.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2695991, ~/Articles/ArticleHandler.aspx, 8/28/2014 9:35:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement